First-in-Human Phase 12 Study of DS3790a Alone and in Combination for Treating Blood Cancers

What this Trial Is About

Researchers are evaluating DS3790a, alone and in combination with other drugs, in people with blood cancers, including hematological malignancies and B-cell Non-Hodgkin Lymphoma. This first-in-human trial aims to study the safety, early effectiveness, and how the body processes DS3790a. The trial is open-label and conducted at multiple centers, involving several groups receiving different doses or combinations. Participants will receive DS3790a alone or with selected combination drugs in various phases, including dose escalation, dose expansion, and randomized phases. One group will receive standard care for comparison. Treatments are given according to the study protocol, with details about dose and schedule specified by investigators. The study includes multiple cohorts to assess different treatment regimens. Participants will be monitored for safety through reporting of side effects and serious adverse events over up to 5 years. Researchers will assess treatment responses, including complete and objective responses, disease control, and survival outcomes. The study involves regular visits, laboratory tests, and assessments to track effectiveness and safety. Participants must comply with scheduled visits and procedures throughout the study, which may last several years.

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies